New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 1, 2013
10:16 EDTBMRNBioMarin achondroplasia treatment granted orphan designation by EMA
Orphan designation granted by the European Commission to BioMarin Europe for modified recombinant human C-type natriuretic peptide for the treatment of achondroplasia on Jan. 24, according to posting to European Medicines Agency site. Reference Link
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 12, 2014
07:53 EDTBMRNLeerink to hold a tour
Subscribe for More Information
November 10, 2014
10:04 EDTBMRNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:02 EDTBMRNBioMarin upgraded to Buy from Neutral at Goldman
Goldman upgraded BioMarin to Buy based on increased confidence in BMN-111 for achondroplasia with expected proof-of-concept data in Q2 2015. The firm now sees a greater than 50% probability of success and peak sales of $900M. Price target raised to $104 from $78.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use